14 completed, 2 recruiting, 1 active not recruiting, 1 terminated. 11 Phase 1, 5 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 11 |
| Phase 2 | 5 | Completed 2, Recruiting 2, Active not recruiting 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow CORT125134: new trials by email Literature Review of CORT125134 trials Research Report on CORT125134
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma Relacorilant, Nab-paclitaxel, Gemcitabine - Adenocarcinoma, Carcinoma, Pancreatic Ductal | Phase 2 | Recruiting | Corcept Therapeutics | 80 | 2026-01-27 | 2026-09-25 |
| Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | Corcept Therapeutics | 270 | 2025-04-11 | 2026-07-16 |
| T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers Relacorilant, Placebo to relacorilant, Moxifloxacin - Healthy | Phase 1 | Completed | Corcept Therapeutics | 36 | 2021-01-22 | 2021-09-14 |
| Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol) Relacorilant, Pembrolizumab - Adrenocortical Carcinoma | Phase 1 | Completed | Corcept Therapeutics | 15 | 2020-09-30 | 2024-02-23 |
| A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects Relacorilant under fasted conditions, Relacorilant after a high-fat meal, Relacorilant after a low-fat meal - Healthy | Phase 1 | Completed | Corcept Therapeutics | 30 | 2020-09-19 | 2023-10-23 |
| A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas Relacorilant, Placebo - Hypercortisolism | Phase 3 | Completed | Corcept Therapeutics | 137 | 2020-07-27 | 2025-09-04 |
| Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Relacorilant, 100 mg and 25 mg, Nab-paclitaxel - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | Terminated | Corcept Therapeutics | 43 | 2020-06-30 | 2023-11-18 |
| A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant Relacorilant - Hepatic Impairment | Phase 1 | Completed | Corcept Therapeutics | 30 | 2020-01-06 | 2023-10-23 |
| A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome Relacorilant, Placebo - Cushing Syndrome | Phase 3 | Completed | Corcept Therapeutics | 152 | 2018-11-15 | 2025-07-16 |
| A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants Relacorilant (3x100 mg softgel capsules), Relacorilant (3x100 mg hard-shell capsules), Relacorilant (6x50mg hard-shell capsules) - Healthy | Phase 1 | Completed | Corcept Therapeutics | 30 | 2018-05-24 | 2018-09-07 |
| Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome relacorilant - Cushing Syndrome | Phase 2 | Active not recruiting | Corcept Therapeutics | 125 | 2018-05-07 | 2026-10-09 |
| Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites Relacorilant 350mg, Itraconazole, Relacorilant 300mg - Healthy | Phase 1 | Completed | Corcept Therapeutics | 52 | 2018-04-10 | 2020-03-24 |
| Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s Midazolam hydrochloride, Metoprolol tartrate, Pioglitazone hydrochloride - Healthy | Phase 1 | Completed | Corcept Therapeutics | 27 | 2018-03-06 | 2018-05-17 |
| Relacorilant Food Effect Study in Healthy Subjects Relacorilant Fasted, Relacorilant with a high fat breakfast, Relacorilant with a moderate breakfast - Healthy, Food-drug Interaction | Phase 1 | Completed | Corcept Therapeutics | 30 | 2018-01-16 | 2018-05-17 |
| Study to Evaluate CORT125134 in Participants With Cushing's Syndrome CORT125134 - Cushing's Syndrome | Phase 2 | Completed | Corcept Therapeutics | 35 | 2016-06-01 | 2019-10-15 |
| Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors Relacorilant with nab-paclitaxel - Solid Tumors | Phase 1 / Phase 2 | Completed | Corcept Therapeutics | 85 | 2016-05-23 | 2022-12-06 |
| A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects CORT125134 - Healthy | Phase 1 | Completed | Corcept Therapeutics | 8 | 2016-04-07 | 2023-10-23 |
| CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) CORT125134, Matching Placebo of CORT125134, Mifepristone - Healthy | Phase 1 | Completed | Corcept Therapeutics | 130 | 2014-09-01 | 2019-08-09 |
ACTH Syndrome, Ectopic (5) · Cushing Syndrome (5) · Diabetes Mellitus, Type 2 (5) · Hypertension (5) · Adrenal Cortex Neoplasms (3) · Adrenocortical Carcinoma (3) · Pituitary ACTH Hypersecretion (3) · Pancreatic Neoplasms (2) · Adenocarcinoma (1) · Adrenal Gland Diseases (1) · Adrenocortical Hyperfunction (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Pancreatic Ductal (1) · Endocrine System Diseases (1) · Endometrial Neoplasms (1)
Corcept Therapeutics (18)
United States (17) · Italy (5) · Germany (4) · Poland (4) · Spain (4) · Austria (3) · Israel (3) · Netherlands (3) · Romania (3) · Bulgaria (2) · Canada (2) · United Kingdom (2) · Belgium (1) · France (1) · Hungary (1)
Andreas G Moraitis, MD (2) · Andreas Moraitis, MD (2) · Joseph Custodio (2) · Joseph Custodio, PhD (2) · Kirsteen Donaldson, FFPM,DM,FRCP (2) · Ada Lee, MD (1) · Danny Nguyen (1) · Danny Nguyen, MD (1) · Hazel Hunt (1) · John McNally (1) · Pui Leung (1) · William Guyer, PharmD (1)
PMID 35058882, PMID 34335465, PMID 41730814
2014 (1)